Transcriptional Control of Human Placental Differentiation
人类胎盘分化的转录控制
基本信息
- 批准号:8461080
- 负责人:
- 金额:$ 31.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-02-01 至 2016-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdenovirusesAgonistBiochemicalCREB1 geneCell Differentiation processCellsCellular MorphologyDIF factorDataDefectDevelopmentDiabetes MellitusEGF geneFeedbackFetal Growth RetardationFunctional disorderGenesGrowth FactorHormonesHumanHuman DevelopmentHypertensionImmunohistochemistryInsulin-Like Growth Factor IInvestigationKnowledgeLaboratoriesLeadMacrophage Colony-Stimulating FactorMessenger RNAMolecularMonitorMononuclearMorbidity - disease rateMorphologyPathogenesisPathologicPathway interactionsPatientsPhenotypePhosphorylationPlacentaPlacentationPost-Translational Protein ProcessingPre-EclampsiaPregnancyProcessProliferatingProteinsRNARegulationResearchRoleSignal PathwaySignal TransductionSignaling MoleculeSmall Interfering RNAStagingSyncytiotrophoblastTFAP2A geneTestingTimeTranscription Factor AP-2 AlphaTranscriptional RegulationVillousbeta catenincytotrophoblastextracellularfetalimmunocytochemistryin vitro Modelin vivoinsightmortalitypublic health relevanceresearch studyresponsetranscription factortrophoblast
项目摘要
DESCRIPTION (provided by applicant): During the development of the human placenta, mononuclear cytotrophoblast (CTB) cells proliferate and fuse to form a syncytiotrophoblast (STB) phenotype. Although this differentiation process is critical for a successful pregnancy, the molecular mechanisms that regulate the process are poorly understood. Our laboratory, utilizing an in vitro model of human CTB cell differentiation, has shown that the transcription factor AP-21 is critical for the differentiation of villous CTB cells to a STB phenotype; and we have characterized some of the upstream regulators and downstream targets of AP-21. Our preliminary studies indicate that several extracellular factors that induce CTB cell differentiation stimulate AP-21 expression that the Wnt-beta-catenin- TCF pathway inhibits AP-21 expression during CTB cell differentiation and that AP-21 expression is abnormal in placentas from patients with severe preeclampsia. We now propose a comprehensive investigation into the mechanisms of which AP-21 regulates CTB cell to STB cell differentiation in the context of normal differentiation and in the context of pathologic conditions characterized by abnormal villous CTB differentiation, such as preeclampsia and IUGR. Specific Aim 1 tests the hypothesis that extracellular factors that induce villous CTB differentiation act, at least in part, by an AP-21-dependent mechanism. Aim 2 tests the hypothesis that there is a negative feedback loop between AP-21 and the Wnt-2-catenin pathway and that extracellular factors that induce CTB cell differentiation act at least in part by inhibiting Wnt-2-catenin-TCF signaling. Aim 3 examines the hypothesis that abnormalities in the AP-21 cascade are responsible, at least in part, for the defective villous CTB cell differentiation in preeclampsia and IUGR. The experiments will utilize an in vitro model of human CTB cell differentiation that closely mimics the in vivo differentiation process. The degree of differentiation will be monitored by cell morphology and by the expression of specific STB marker genes. The studies should provide new insights into the molecular mechanisms of placental differentiation and the pathogenesis of the defective placentation in preeclampsia and IUGR. These insights in turn may lead to development of new strategies to treat placental defects that result in fetal morbidity and mortality.
描述(由申请人提供):在人胎盘的发育过程中,单核细胞滋养细胞(CTB)细胞增殖并融合形成合胞滋养细胞(STB)表型。尽管这种分化过程对成功怀孕至关重要,但调控这一过程的分子机制尚不清楚。我们的实验室利用人类CTB细胞分化的体外模型,已经表明转录因子AP-21对绒毛CTB细胞向STB表型的分化至关重要;我们已经描述了AP-21的一些上游调节因子和下游目标。我们的初步研究表明,几种诱导CTB细胞分化的细胞外因子刺激AP-21的表达,wnt - β -catenin- TCF通路抑制CTB细胞分化过程中AP-21的表达,严重子痫前期患者胎盘中AP-21的表达异常。我们建议对AP-21在正常分化和以子痫前期、IUGR等异常绒毛状CTB分化为特征的病理条件下调控CTB细胞向STB细胞分化的机制进行全面研究。特异性目的1验证了细胞外因子诱导绒毛CTB分化的假设,至少部分是通过ap -21依赖机制起作用的。Aim 2验证了AP-21与Wnt-2-catenin通路之间存在负反馈回路的假设,以及诱导CTB细胞分化的细胞外因子至少部分通过抑制Wnt-2-catenin- tcf信号传导而起作用。目的3检验了AP-21级联异常至少在一定程度上导致子痫前期和IUGR中绒毛CTB细胞分化缺陷的假设。实验将利用人CTB细胞的体外分化模型,密切模仿体内分化过程。分化程度将通过细胞形态和特定STB标记基因的表达来监测。这些研究将为子痫前期胎盘分化的分子机制以及胎盘缺陷的发病机制和IUGR提供新的见解。这些见解反过来可能导致治疗导致胎儿发病率和死亡率的胎盘缺陷的新策略的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stuart Handwerger其他文献
Stuart Handwerger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stuart Handwerger', 18)}}的其他基金
Transcriptional Control of Human Placental Differentiation
人类胎盘分化的转录控制
- 批准号:
8214647 - 财政年份:2011
- 资助金额:
$ 31.07万 - 项目类别:
Transcriptional Control of Human Placental Differentiation
人类胎盘分化的转录控制
- 批准号:
8605896 - 财政年份:2011
- 资助金额:
$ 31.07万 - 项目类别:
Transcriptional Control of Human Placental Differentiation
人类胎盘分化的转录控制
- 批准号:
8040063 - 财政年份:2011
- 资助金额:
$ 31.07万 - 项目类别:
TRAINING IN DEVELOPMENTAL AND PERINATAL ENDOCRINOLOGY
发育和围产期内分泌学培训
- 批准号:
6125509 - 财政年份:1994
- 资助金额:
$ 31.07万 - 项目类别:
TRAINING IN DEVELOPMENTAL AND PERINATAL ENDOCRINOLOGY
发育和围产期内分泌学培训
- 批准号:
2195723 - 财政年份:1994
- 资助金额:
$ 31.07万 - 项目类别:
TRAINING IN DEVELOPMENTAL AND PERINATAL ENDOCRINOLOGY
发育和围产期内分泌学培训
- 批准号:
2801503 - 财政年份:1994
- 资助金额:
$ 31.07万 - 项目类别:
Training in Developmental and Perinatal Endocrinology
发育和围产期内分泌学培训
- 批准号:
7227841 - 财政年份:1994
- 资助金额:
$ 31.07万 - 项目类别:
TRAINING IN DEVELOPMENTAL AND PERINATAL ENDOCRINOLOGY
发育和围产期内分泌学培训
- 批准号:
6403208 - 财政年份:1994
- 资助金额:
$ 31.07万 - 项目类别:
Training in Developmental and Perinatal Endocrinology
发育和围产期内分泌学培训
- 批准号:
7417478 - 财政年份:1994
- 资助金额:
$ 31.07万 - 项目类别:
Training in Developmental and Perinatal Endocrinology
发育和围产期内分泌学培训
- 批准号:
7847488 - 财政年份:1994
- 资助金额:
$ 31.07万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 31.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 31.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 31.07万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 31.07万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 31.07万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 31.07万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 31.07万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 31.07万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 31.07万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 31.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)